Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal.

Slides:

Advertisements

Similar presentations

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Advertisements

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Shin-Ichi Nishikawa, MD, PhD

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Expression of FcγRIII (CD16) on human peripheral blood eosinophils increases in allergic conditions Francis Davoine, MSc, Sophie Lavigne, MSc, Jamila.

Vitamin D enhances production of soluble ST2, inhibiting the action of IL-33 Paul E. Pfeffer, MRCP, Yin-Huai Chen, MSc, Grzegorz Woszczek, PhD, Nick C.

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Allergic Rhinitis and Its Impact on Asthma

Effect of interleukin-5 and granulocyte-macrophage colony stimulating factor on in vitro eosinophil function: Comparison with airway eosinophils Julie.

Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors Philippe Gosset,

The effect of omalizumab on nasal allergic inflammation

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

The histamine-cytokine network in allergic inflammation

Badrul A. Chowdhury, MD, PhD

Histamine in the immune regulation of allergic inflammation

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis Albert Jen, MD, Fuad Baroody, MD, Marcy de Tineo,

Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis

Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A Satoshi Matsukura, MD, Fumio Kokubu,

Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure Margherita Tomassini, MDa, Laura Magrini, MDa, Guido De.

Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: An antiallergic activity

Cristiana Stellato, MD, PhDa, Jun Atsuta, MD, PhDb, Carol A

Eosinophil peroxidase stimulates the release of granulocyte-macrophage colony- stimulating factor from bronchial epithelial cells Shinji Motojima, MDa,

Practice Notes from the AAAAI

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic.

Cytokines and allergy Journal of Allergy and Clinical Immunology

The effects of glucocorticoids on human eosinophils

A review of the current guidelines for allergic rhinitis and asthma

Rhinophototherapy: A new therapeutic tool for the management of allergic rhinitis Andrea I. Koreck, MD, PhD, Zsanett Csoma, MD, Laszlo Bodai, Ferenc Ignacz,

Early decreases in blood eosinophil levels with reslizumab

Pathophysiology of the inflammatory response

News & Notes Journal of Allergy and Clinical Immunology

Delayed eosinophil programmed cell death in vitro: A common feature of inhalant allergy and extrinsic and intrinsic atopic dermatitis Bettina Wedi, MD,

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Epithelial cells as regulators of airway inflammation

Peter Vadas, MD, PhD, Boris Perelman, PhD, Gary Liss, MD, MS

Effect of ozone and nitrogen dioxide on the release of proinflammatory mediators from bronchial epithelial cells of nonatopic nonasthmatic subjects and.

What is an “eosinophilic phenotype” of asthma?

Eosinophilia and gastrointestinal symptoms after ingestion of shiitake mushrooms Aaron M. Levy, MDa, Hirohito Kita, MDb, Sidney F. Phillips, MDa, Paul.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids Keisuke.

Ganglioside GQ1b enhances Ig production by human PBMCs

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis Robert P. Harvey, MD, Carolyn Comer, MD, Barbara Sanders, MD, Ross Westley,

Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: Comparison of patients with and without anti-FcϵRI or anti-IgE autoantibodies

The role of CD28-B7 costimulation in allergen-induced cytokine release by bronchial mucosa from patients with moderately severe asthma James L. Lordan,

News & Notes Journal of Allergy and Clinical Immunology

Pathogenesis of allergic rhinitis

A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein.

Harald Renz, MD, Chaya Brodie, PhD, Katherine Bradley, BS, Donald Y. M

Chemokines in seasonal allergic rhinitis

Larry L. Thomas, PhD, Michelle D. Haskell, Emmanuel U

Seasonal rhinitis and azelastine: Long- or short-term treatment

Practice Notes from the AAAI

Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis Toyoyuki Hanazawa, MD, PhD, Julio.

Corticosteroids in the treatment of pediatric allergic rhinitis

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Nedocromil sodium and airway inflammation in vivo and in vitro

Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: Effect of topical corticosteroids Pota Christodoulopoulos, BSca,

Robert P. Schleimer, PhD Journal of Allergy and Clinical Immunology

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

TH2 Cytokine-enhanced and TGF-β-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-γ.

IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy Kayhan T. Nouri-Aria, PhD, FRCPath, Charles.

Comparison of ciliary activity and inflammatory mediator release from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic.

Differences in proliferation of the hematopoietic cell line TF-1 and cytokine production by peripheral blood leukocytes induced by 2 naturally occurring.

Bruce K. Bacot, MD, Mary E. Paul, MD, Maritza Navarro, MD, Stuart L

News & Notes Journal of Allergy and Clinical Immunology

Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma Oliver Noga, MD, Gerald Hanf, MD,

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

Advances in mechanisms of allergic disease in 2016

Presentation transcript:

Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis Muntasir M. Abdelaziz, MRCP, Jagdish L. Devalia, PhD, Omer A. Khair, MRCP, Hasan Bayram, MD, Andrew J. Prior, FRCS, Robert J. Davies, FRCP Journal of Allergy and Clinical Immunology Volume 101, Issue 3, Pages 410-420 (March 1998) DOI: 10.1016/S0091-6749(98)70256-8 Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 1 Effect of 10-9 to 10-3 mol/L fexofenadine (A); 10 -9 to 10-3 mol/L fexofenadine plus eosinophils (B); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (C) on changes in electrical resistance of HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season. Results are expressed as percentage change in electrical resistance from baseline. SF-medium , serum-free medium; Fexo, fexofenadine; Eos, eosinophils; and LB, latex beads. (n = 6 for each set of experiments; *p < 0.05 for cultures treated with eosinophils plus latex beads vs cultures treated with eosinophils plus latex beads in the presence of 10-9 to 10-3 mol/L fexofenadine). Journal of Allergy and Clinical Immunology 1998 101, 410-420DOI: (10.1016/S0091-6749(98)70256-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 2 Release of RANTES from HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season after incubation with eosinophils with or without latex beads (A); 10-9 to 10-3 mol/L fexofenadine (B); 10-9 to 10-3 mol/L fexofenadine plus eosinophils (C); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (D). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology 1998 101, 410-420DOI: (10.1016/S0091-6749(98)70256-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 3 Release of IL-8 from HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season after incubation with eosinophils with or without latex beads (A); 10-9 to 10-3 mol/L fexofenadine (B); 10-9 to 10-3 mol/L fexofenadine plus eosinophils (C); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (D). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology 1998 101, 410-420DOI: (10.1016/S0091-6749(98)70256-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 4 Release of GM-CSF from HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season after incubation with eosinophils with or without latex beads (A); 10-9 to 10-3 mol/L fexofenadine (B); 10-9 to 10-3 mol/L fexofenadine plus eosinophils (C); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (D). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology 1998 101, 410-420DOI: (10.1016/S0091-6749(98)70256-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 5 Release of sICAM-1 from HNEC cultures established from patients with seasonal allergic rhinitis outside pollen season after incubation with eosinophils with or without latex beads (A); 10-9 to 10-3 mol/L fexofenadine (B); 10-9 to 10-3 mol/L fexofenadine plus eosinophils (C); and 10-9 to 10-3 mol/L fexofenadine plus eosinophils plus latex beads (D). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology 1998 101, 410-420DOI: (10.1016/S0091-6749(98)70256-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 6 ECP release from eosinophils after incubation with latex beads with or without HNEC (A) and latex beads with or without HNEC with or without 10 -9 to 10-3 mol/L fexofenadine (B). Results are expressed as median values (horizontal line) and individual values. SF-medium, serum free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology 1998 101, 410-420DOI: (10.1016/S0091-6749(98)70256-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 7 Effect of HNEC conditioned medium (CM) with or without 10-9 to 10-3 mol/L fexofenadine (A) and serum-free medium with or without 0.01 to 1.0 μmol/L PAF (B) on eosinophil chemotaxis in vitro. Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; PAF, platelet activating factor; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology 1998 101, 410-420DOI: (10.1016/S0091-6749(98)70256-8) Copyright © 1998 Mosby, Inc. Terms and Conditions

FIG. 8 Effect of HNEC-conditioned medium (CM) with or without 10-9 to 10-3 mol/L fexofenadine on adherence of eosinophils to human endothelial cells in vitro. Results are expressed as median values (horizontal line) and individual values. SF-medium, serum-free medium; n = 6 for each set of experiments. Journal of Allergy and Clinical Immunology 1998 101, 410-420DOI: (10.1016/S0091-6749(98)70256-8) Copyright © 1998 Mosby, Inc. Terms and Conditions